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The rate adaptive sensors applied to cardiac pacing should respond as promptly as the normal sinus node with an highly speciﬁc
and sensitive detection of the need of increasing heart rate. Sensors operating alone may not provide optimal heart responsiveness:
central venous pH sensing, variations in the oxygen content of mixed venous blood, QT interval, breathing rate and pulmonary
minute ventilation monitored by thoracic impedance variations, activity sensors. Using sensors that have diﬀerent attributes
but that work in a complementary manners oﬀers distinct advantages. However, complicated sensors interactions may occur.
Hemodynamic sensors detect changes in the hemodynamic performances of the heart, which partially depends on the autonomic
nervous system-induced inotropic regulation of myocardial ﬁbers. Speciﬁc hemodynamic sensors have been designed to measure
diﬀerent expression of the cardiac contraction strength: Peak Endocardial Acceleration (PEA), Closed Loop Stimulation (CLS)
and TransValvular Impedance (TVI), guided by intraventricular impedance variations. Rate-responsive pacing is just one of
the potential applications of hemodynamic sensors in implantable pacemakers. Other issues discussed in the paper include:
hemodynamic monitoring for the optimal programmation and follow up of patients with cardiac resynchronization therapy;
hemodynamic deterioration impact of tachyarrhythmias; hemodynamic upper rate limit control; monitoring and prevention of
vasovagal malignant syncopes.
1.Introduction
The ﬁrst implantable cardiac pacemakers were designed to
pace at a ﬁxed rate without any attempt to mimic heart rate
changes. Since there, technologically advanced pacemakers
were introduced that adjusted the pacing rate by sensing
the patient’s intrinsic atrial activity and regulating the
ventricular pacing rate accordingly.
Successively, by the mid-1980s, artiﬁcial sensors were
introduced in order to overcome problems with chrono-
tropic incompetence in the pacemaker-recipient population.
Theprevalenceofchronotropicincompetenceisestimatedto
be present in 20% to 58% of pacemaker recipients [1, 2]. In
these patients, rate responsive pacing has been demonstrated
to improve cardiac output and exercise tolerance when
compared with ﬁxed rate pacing [3]; many older studies
have shown that exercise capacity, stroke volume changes
with exercise, and maximum oxygen consumption depend
primarily on heart rate change in most subjects [4–7].
Aimofthepresentpaperistoaddressthediﬀerenthemo-
dynamic sensors currently implemented in rate responsive
pacemakers.
2. RateResponsiveness TraditionalSensors
Ideally, the rate-adaptive sensors should be capable of mim-
icking the sinoatrial’s node ability to provide an appropriate
heart rate response to the physiological and psychological
stress and rate decay during recovery after exercise should
match metabolic needs [8].
Many diﬀerent types of rate-modulated cardiac pace-
makers have been investigated.
In the mid-1970s, Cammilli et al. [9] provided the ﬁrst
implantable device using central venous pH sensing; the
conceptwasthatthedecreaseofcentralvenouspHassociated
with exercise would increase pacemaker rate; unfortunately
this sensor was not found to be stable in the long-term, and
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Variations in the oxygen content of mixed venous blood,
measured as the right ventricular oxygen saturation, have
been successively evaluated as indicators for controlling the
pacing rate [10]. The main technical problem involved in
using this biosensor was that the signal received from the
oxygen sensor showed dynamic ﬂuctuations that depend on
numerous factors: changing conditions of light reﬂection
around the electrode, movements of erythrocytes with dif-
ferent oxygen saturation levels, incomplete mixing of blood,
position of the oxygen sensor within the right ventricular
cavity, and the direction of the light beam emitted [11].
The QT interval, which is the interval between the pacing
stimulus to the peak of the T wave, is another parameter
that has been investigated for controlling the pacing rate
[12, 13]. This interval is modiﬁed by changes in circulating
or locally released cathecholamines, constituting a physio-
logical indicator for adapting the pacing rate in response
to increased sympathetic activity induced by exercise or
emotion. However, the QT interval may be unreliable in T
wave undersensing and is aﬀected by drugs and electrolyte
alterations; besides, as it requires ventricular pacing, it
cannot be used in AAIR mode [8].
Respiration has been used as a physiological sensor
to restore physiological rate control of the heart with a
respiratory-dependent pacemaker [14]. Sensing of breathing
rate and tidal volume was monitored by impedance varia-
tions initially detected between the pacemaker casing and
an auxiliary lead implanted subcutaneously. The use of the
respiratory rate as a pacing sensor was demonstrated to
signiﬁcantly improve exercise tolerance compared to ﬁxed
rate pacing [15]. A successful approach calculated minute
ventilation by impedance measurements made between a
bipolar pacemaker lead and the pulse generator case. This
respiratory pacemaker changes the cardiac stimulation rate
in response both to the rate of respiration and to the tidal
volume, both of which make up minute ventilation, a value
that has been demonstrated to correlate well with exercise
[16]. Limitations of this sensor include lower reliability in
subjects with obstructive pulmonary disease, false positive
reaction in hyperventilation, or interference with posture
[11].
Activity sensors are the older, and by far, the most pop-
ular and more widely used. Activity may be acknowledged
either by a piezoelectric crystal which recognizes body move-
ments or by an accelerometer that identiﬁes the postural
changes and the body movements related to physical activity
[8].The main limitation of this kind of sensor is that the
rate of adaptation may not be proportional to the metabolic
demand. For example, activity sensors may underrespond
to activities in which there is minimal thoracic movement
such as smooth callisthenics movements, treadmill gradient
change, and cycle ergometer exercise. These sensors may
also yield an excessive heart rate response to tempo changes,
staircase decent, and upper arm activity [11].
As shown before, sensors operating alone may not
provide optimal heart rate responsiveness. Consequently,
sensors that have diﬀerent attributes but work in a comple-
mentary manner oﬀe r sa d v a n t a g e s[ 17]. However, compli-
cated sensor interactions may occur.
The most frequent association includes the combination
of an activity sensor which allows a rapid response during
exercise and a metabolic sensor such as minute ventilation or
QT interval which provides an increasing pacing rate during
mental stress.
The LIFE study [18], which compared the relative beneﬁt
of a blended sensor (accelerometer and minute ventilation)
versus single sensor (accelerometer), has demonstrated that
the use of dual-sensor pacemaker restored chronotropic
response and allowed a signiﬁcant improvement of exercise
capacity when compared with the use of only the accelerom-
eter sensor. This seems particularly true in patients with
marked chronotropic incompetence [19].
Pacemaker sensor features, alone or in combination, are
frequently used in default setting; the role of individual
optimizationoftheactualsophisticatedsensorsinimproving
quality of life and exercise capacity requires further investi-
gation. A recent study has demonstrated that after 1 month
of individual optimization of rate response pacemakers,
exercise capacity was improved and maximum heart rate
increased, although quality of life remained unchanged [20].
Besides, The ADEPT study [21] which was a single-blind
randomized controlled trial comparing dual-chamber with
rate-modulated dual-chamber pacing in patients with pre-
dominant sinus node dysfunction, failed to demonstrate the
eﬀectiveness of rate modulation in improving the functional
status or quality of life.
3. RateResponsiveness HaemodynamicSensors
Hemodynamic sensors detect changes in the hemodynamic
performances of the heart, which partially depends on the
autonomic nervous system-induced inotropic regulation of
myocardial ﬁbers. Under physiological conditions, inotropic
and chronotropic properties are controlled in order to
synergistically modulate the cardiac output according to the
metabolic demand. Once the required hemodynamic com-
pensation is achieved, the system is downregulated. Thanks
tothisintrinsicnegativefeedback,inthecaseofchronotropic
incompetence, assessment of cardiac contractility would
allow timely rate adaptation with reduced risk of overpacing.
Speciﬁc haemodynamic sensors have been designed to
measure diﬀerent expression of the cardiac contraction
strength.
Themainintracardiacsensorswhichtodayseemtobetter
measure surrogate parameters of hemodynamics include
Peak Endocardial Acceleration (PEA) (Sorin Group, Italy),
ventricular impedance guiding a Closed Loop Stimulation
(CLS) (Biotronik, Germany), and Transvalvular Impedance
(TVI (Medico, Italy).
3.1. Peak Endocardial Acceleration (PEA) (Figure 1). Theo-
retically, the contractile state of the heart can be identiﬁed in
terms of ventricular mechanics by the maximum velocity of
shortening of unloaded myocardial contractile elements.
More than 20 years ago, an experimental rate responsive
pacemaker based on the detection of the peak dP/dt of
the right ventricle to drive the pacing rate was investigatedCardiology Research and Practice 3
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Figure 1: Peak Endocardial Acceleration (PEA) sensor (Sorin Group, Italy). An accelerometer mounted on the tip of a pacing lead placed
in the right ventricle detects PEA-I, related to the isovolumic contraction (and the ﬁrst cardiac tone) and PEA-II, related to the isovolumic
relaxation (and the second cardiac tone).
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Figure 2: Closed Loop Stimulation (CLS) system (Biotronik, Germany). (a) Changes in intracardiac impedance are closely related to
myocardium-blood ratio in the volume around the ventricular tip. (b) An increase in blood volume (and the consequent solid angle)
produces a decrease in intracardiac impedance (Z). (c) An enhanced contractility induces an increase of impedance around the electrode tip
(morphological modiﬁcation of impedance curve moves it to the left).4 Cardiology Research and Practice
[22]; while the peak dP/dt of the right ventricle has been
demonstrated to reﬂect quite well the contractile property
of the total heart, theoretically the main diﬃculties could be
in long-term sensing of dP/dt, due to tissue encapsulation
and ventricular muscle pressing on the membrane of the
transducer.
The measurement of endocardial vibration, by means
of an accelerometer in the right ventricle only during the
isovolumetric phase, allows to assess a parameter of heart
contractility: the systolic isovolumic peak acceleration, that
was called “Peak Endocardial Acceleration (PEA).” PEA is
recorded by an accelerometer mounted in the tip of a
dedicated pacing lead which is sensitive to right ventricle
wall vibrations generated by the mechanical activity of the
heart; it was demonstrated to increase during adrenergic
stimulation and to follow the changes in heart rate [23]
Interestingly, even if the sensor is located in the right ven-
tricle, the PEA amplitude is determined by the contraction
strength in the left ventricle, where the systolic myocardial
vibrations are generated. PEA dynamic monitoring has been
demonstrated to provide fast pacing rate responses with
long-term performance of sensor lead also in patients with
heart failure and wide QRS complexes [24].
More recently, another application of the intracardiac
accelerometer was reported. In addition to the ﬁrst PEA
(PEA I), recorded during the isovolumic systole, the sensor
can detect a further signal, which is designated as PEA II.
PEA II is recorded during the isovolumic relaxation and
corresponds to the second cardiac sound. Experimental
studies indicated that the PEA II amplitude reﬂects the
rate of rise of the pressure gradient across the aortic valve
at the time of valve closure, which depends on both the
rate of ventricular pressure reduction (negative dP/dt) and
the afterload [25], although its role in measuring diastolic
function has not been conﬁrmed yet.
Moreover, the PEA signal can be recorded at diﬀerent
locations in the heart; it has been recently demonstrated
that the PEA signal measured in the atrium is reliable and
proportional to the signal recorded in the ventricle [26].
The main disadvantage of the PEA recording comes for
the need of a dedicated lead mounting the intracardiac
accelerometer, which may limit the number of patients who
could beneﬁt from this sensor system.
3.2.IntracardiacVentricularImpedance(Figure2). Anattrac-
tive method to obtain a physiological pacemaker system
wouldbetheintegrationofthepacingdeviceintothenatural
cardiocirculatory system. This concept has been realized in
the Closed Loop Stimulation (CLS) system, which converts
information from the circulation applied to the right ventri-
cle into a concordant heart rate [27]. Even under pathophys-
iological conditions, the dynamics of myocardial contraction
stillreﬂecttheinformationcomingfromthecirculation[28].
Inotropic regulation aﬀects myocardial contractility, which
consequently reﬂects information about the hemodynamic
state and requirements. Based on that relationship, the CLS
pacemakers from Biotronik (Biotronik GmbH εtC o . ,G e r -
many) detect changes in myocardial contraction dynamics
through intracardiac measurement and transfer them into
individualpacingrates.Inthesepacemakers,load-dependent
changes in myocardial contractility reﬂect variations in the
unipolar intracardiac impedance, measured between the
ventricular electrode tip of a conventional bipolar lead and
the pacemakers case. During myocardial contraction, the
proportions of blood and myocardium vary in the close
vicinity of the electrode tip. Since the speciﬁc resistance of
blood diﬀers signiﬁcantly from that of the myocardium, the
dynamics of the myocardial contraction can be well detected
in a time-course impedance curve. Therefore, by monitoring
the unipolar intracardiac impedance, changes in myocardial
contractility can reliably be measured.
In a previous study [29], it has been demonstrated
that CLS-driven pacemakers, in a population of patients
with chronotropic incompetence, allowed overall cardio-
vascular responses comparable to those of healthy indi-
viduals throughout incremental exercise. Furthermore, the
pacemaker provided appropriate rate response up to the
anaerobic threshold. Additionally, the rate decay algorithm
appeared to result in physiologically appropriate haemody-
namics during the initial phase of recovery.
The role of CLS has also been well established in
patients with refractory and recurrent vasovagal syncope
evenduringalong-termfollow-up[30–32].Therationalefor
the eﬀectiveness of CLS in these situations is that during a
vasovagal syncope the diminished venous return stimulates
a sympathetic compensatory tone that leads to a positive
inotropic eﬀect. Since ventricular ﬁlling is reduced, left
ventricular systolic pressure may increase participating in
a baroreceptor induction of bradycardia, thereby creating a
paradoxical situation: increased inotropic eﬀect associated
with decreased chronotropic state. This anomalous situation
inhibits sympathetic activity and promotes a reactive vagal
eﬀect that causes vasovagal syncope by increasing peripheral
vasodilatation and reﬂex bradycardia. The CLS detection
of the increased contractility in the ﬁrst stage of vasovagal
syncope could activate atrioventricular sequential pacing
that may anticipate withdrawal of sympathetic tone and
counterbalance the increase in vagal tone, preventing in this
way arterial hypotension, bradycardia, and ﬁnally syncope.
The fourth generation of CLS devices, capable of oper-
ating on both sensed and paced ventricular beats, have
overcomethemajorlimitationoftheprevioussystemswhich
required permanent ventricular pacing.
3.3. Transvalvular Impedance (TVI) (Figures 3 and 4).
Cardiac impedance could be applied to detect changes in
end-diastolic ventricular volume as well as volume changes
from diastolic to end-systolic conditions provided that the
absolute impedance is recorded instead of just peak-to-
peak variation. This is possible if high-quality, stable, and
noise-free impedance signals are derived. This goal has been
achieved thanks to a recently developed recording method,
wherebyimpedance is detected between the right atrium and
the right ventricle, called transvalvular impedance (TVI).
TVI is a regular periodic waveform with a minimum value
during atrial systole (theoretically corresponding to the end-
diastolic phase) and a maximum at the end of the QT period
(theoretically corresponding to the end-systolic phase) [33].Cardiology Research and Practice 5
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Figure 3: Trans Valvular Impedance (TVI) system (Medico, Italy). The impedance signal is derived between right atrium and the ventricle,
by the tip (a) or the ring (b) electrodes of standard pacing leads.
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Figure 4: Trans Valvular Impedance (TVI) system (Medico, Italy). TVI waveform mirrors the time-course of ventricular volume along the
cardiac cycle, detecting by M-mode Echo. TVI increases during ventricular systole and decreases during passive and active ﬁlling period.
The minimum TVI, which is recorded close to the maximum
ventricular ﬁlling, is sensitive to all conditions known to
modify the preload. The maximum TVI, which is recorded
when the ventricular systole is completed, corresponds to
the minimal ventricular volume (end-systolic volume) and
is sensitive to changes in cardiac contractility. The relative
variations, that could surrogate the end-diastolic and end-
systolic volumes, left ventricular ejection fraction and stroke
volume, deﬁne a cardiac inotropic index fully independent
from preload eﬀects, which is a direct expression of the
autonomic nervous system regulation of the heart [34].
Even if TVI data are referred to the right ventricle, the
essential haemodynamic information holds for the systemic
circulation as well, since under steady conditions, the stroke
volume is the same in the pulmonary artery and the aorta.
Wheninotropic indexwasusedtodrivearate-responsive
stimulator (SOPH ` OS by Medico, Padova, Italy), the TVI-
indicated pacing rate proved a precise replication of the indi-
vidual sinus rate in patients with physiological chronotropic
competence [35].
The ability to discriminate the hemodynamic expres-
sion of cardiac contractility from the preload eﬀects is6 Cardiology Research and Practice
an important advance in hemodynamic sensor technology,
which is expected to improve pacing rate regulation in all
circumstances entailing a modiﬁcation in venous return.
Furthermore, the prospect of obtaining diagnostic informa-
tion on the trend of diastolic ventricular ﬁlling, as well as on
the ejected blood volume, in changing daily-life conditions
by an implanted device, makes TVI an appealing new tool in
the medical care of pacemaker patients.
4. ClinicalImpact of Hemodynamic Sensors
Rate-responsive pacing is just one of the many potential
applications of haemodynamic sensors in implantable pace-
makers, always blending with activity sensors. Specially in
heart failure patients they could assure an optimal upper
rate limit control, reducing deleterious inappropriate rate
response induced by motion sensors [36].
If applied to a cardioverter deﬁbrillator device (ICD),
they could be used to discriminate the supraventricular and
ventricular malignant tachyarrhythmias: its use could be a
marker of hemodynamic deterioration during tachyarrhyth-
mias and guide the ATP or shock therapy [37].
TVI has been proposed for beat-to-beat detection of
mechanical ventricular activity and capture conﬁrmation
[38], with a haemodynamic alternative to the electrical auto-
capture control of the eﬀective ventricular pacing.
Clinical trials support the use of these tools to recognize
the prodromes of neurally mediated syncope and to trigger a
protective increase in the cardiac pacing rate: this one could
be possible as with PEA sensor [39] and with CLS pacing
[30–32].
Closed loop stimulation and peak endocardial acceler-
ation based algorithm has been recently demonstrated to
be eﬀective in atrioventricular delay optimal and dynamic
programmation [40, 41]. Besides, very recently, Becher et
al. [42] have published the results of an animal study in
which implant-based impedance showed a strong inverse
correlation with changes of directly measured intrathoracic
ﬂuid accumulation.
In this setting, intrathoracic impedance monitoring, a
hemodynamic sensor which is an index of changes of ﬂuid
status, even if not developed to drive heart rate, has been
shown to reduce hospitalizations in heart failure patients
[43]. Besides, when combined with other heart failure
device diagnostic information such as long-lasting atrial
ﬁbrillation especially with rapid ventricular rate, low patient
activity, high night heart rate, low heart rate variability could
predict the clinical deterioration of ambulatory heart failure
subjects, enhancing the ability to risk-stratify patients for
subsequent heart failure events [44].
In cardiac resynchronization therapy, hemodynamic sen-
sors could provide indications about the most appropriate
left ventricular pacing site [45] or the best interventricular
delay to apply [24–46].
Furthermore, hemodynamic sensors might play a role
in the long-term monitoring of heart failure, helping the
physician in the individual care of each patient. This last task
would be quite appealing, especially if the diagnostic system
gives information on the trend of the main hemodynamic
variables such as the preload, the afterload, the stroke
volume, and left ventricular ejection fraction [47].
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